Mike Kratky
Stock Analyst at Leerink Partners
(2.65)
# 2,013
Out of 5,113 analysts
39
Total ratings
40.91%
Success rate
29.28%
Average return
Main Sectors:
Stocks Rated by Mike Kratky
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TXG 10x Genomics | Maintains: Market Perform | $22 → $20 | $21.08 | -5.12% | 5 | Jan 27, 2026 | |
| PEN Penumbra | Downgrades: Market Perform | $374 | $359.03 | +4.17% | 2 | Jan 16, 2026 | |
| BSX Boston Scientific | Maintains: Outperform | $127 → $128 | $93.79 | +36.48% | 2 | Oct 1, 2025 | |
| INSP Inspire Medical Systems | Maintains: Market Perform | $116 → $97 | $82.01 | +18.28% | 7 | Aug 15, 2025 | |
| MDT Medtronic | Initiates: Outperform | $110 | $100.79 | +9.14% | 1 | Jun 16, 2025 | |
| BBNX Beta Bionics | Initiates: Outperform | $28 | $14.78 | +89.45% | 1 | Feb 24, 2025 | |
| DXCM DexCom | Maintains: Outperform | $90 → $87 | $73.36 | +18.59% | 2 | Oct 25, 2024 | |
| TNDM Tandem Diabetes Care | Upgrades: Outperform | $34 → $45 | $19.11 | +135.48% | 2 | Apr 25, 2024 | |
| NPCE NeuroPace | Initiates: Outperform | $22 | $15.60 | +41.03% | 1 | Jan 30, 2024 | |
| PODD Insulet | Initiates: Outperform | $184 | $258.20 | -28.74% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $42 | $36.20 | +16.02% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $342 | $522.04 | -34.49% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $75 | $81.86 | -8.38% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $37 | $30.02 | +23.25% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $9 | $34.11 | -73.61% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $325 → $50 | $25.43 | +96.62% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $45 | $1.25 | +3,500.00% | 2 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $145 → $315 | $496.54 | -36.56% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $26 → $31 | $71.10 | -56.40% | 2 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $14 | $26.08 | -46.32% | 1 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $40 | $33.62 | +18.98% | 1 | Aug 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $392 → $384 | $57.65 | +566.09% | 1 | Aug 11, 2022 |
10x Genomics
Jan 27, 2026
Maintains: Market Perform
Price Target: $22 → $20
Current: $21.08
Upside: -5.12%
Penumbra
Jan 16, 2026
Downgrades: Market Perform
Price Target: $374
Current: $359.03
Upside: +4.17%
Boston Scientific
Oct 1, 2025
Maintains: Outperform
Price Target: $127 → $128
Current: $93.79
Upside: +36.48%
Inspire Medical Systems
Aug 15, 2025
Maintains: Market Perform
Price Target: $116 → $97
Current: $82.01
Upside: +18.28%
Medtronic
Jun 16, 2025
Initiates: Outperform
Price Target: $110
Current: $100.79
Upside: +9.14%
Beta Bionics
Feb 24, 2025
Initiates: Outperform
Price Target: $28
Current: $14.78
Upside: +89.45%
DexCom
Oct 25, 2024
Maintains: Outperform
Price Target: $90 → $87
Current: $73.36
Upside: +18.59%
Tandem Diabetes Care
Apr 25, 2024
Upgrades: Outperform
Price Target: $34 → $45
Current: $19.11
Upside: +135.48%
NeuroPace
Jan 30, 2024
Initiates: Outperform
Price Target: $22
Current: $15.60
Upside: +41.03%
Insulet
Oct 16, 2023
Initiates: Outperform
Price Target: $184
Current: $258.20
Upside: -28.74%
Oct 16, 2023
Initiates: Outperform
Price Target: $42
Current: $36.20
Upside: +16.02%
Oct 16, 2023
Initiates: Outperform
Price Target: $342
Current: $522.04
Upside: -34.49%
Oct 16, 2023
Initiates: Market Perform
Price Target: $75
Current: $81.86
Upside: -8.38%
Oct 16, 2023
Initiates: Outperform
Price Target: $37
Current: $30.02
Upside: +23.25%
Oct 16, 2023
Initiates: Outperform
Price Target: $9
Current: $34.11
Upside: -73.61%
Aug 15, 2023
Downgrades: Market Perform
Price Target: $325 → $50
Current: $25.43
Upside: +96.62%
Jan 24, 2023
Maintains: Outperform
Price Target: $33 → $45
Current: $1.25
Upside: +3,500.00%
Dec 20, 2022
Maintains: Outperform
Price Target: $145 → $315
Current: $496.54
Upside: -36.56%
Dec 15, 2022
Maintains: Market Perform
Price Target: $26 → $31
Current: $71.10
Upside: -56.40%
Nov 4, 2022
Maintains: Outperform
Price Target: $12 → $14
Current: $26.08
Upside: -46.32%
Aug 15, 2022
Maintains: Outperform
Price Target: $32 → $40
Current: $33.62
Upside: +18.98%
Aug 11, 2022
Maintains: Outperform
Price Target: $392 → $384
Current: $57.65
Upside: +566.09%